Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery

Back to Search
Print
Bookmark Trial

NCT00150280

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Shenyang, Liaoning, 110001, China
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postoperative Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Undergone uncomplicated orthopedic surgery or abdominal gynecological surgery under epidural anesthesia

- Baseline pain intensity of more than 45 mm as measured by VAS and a severity of pain graded as moderate or severe on the categorical pain intensity scale

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- A previous history of intolerance or hypersensitivity to any NSAIDs, cyclooxygenase
inhibitor, sulfonamides, or any analgesic, or to drugs with similar chemical
structures

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Postoperative PainCompare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery
NCT00150280
  1. Shenyang, Liaoning
  2. Beijing,
  3. Beijing,
  4. Beijing,
  5. Shanghai,
  6. Shanghai,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Postoperative PainEfficacy And Safety Of Parecoxib IV/IM 40 Mg Vs Placebo Following Sub Muscular Breast Augmentation
NCT00435747
Female
18 Years+
years
MULTIPLE SITES
Postoperative PainMorphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy
NCT00346268
  1. Essen,
  2. Heidelberg,
  3. Koeln,
  4. Reutlingen,
Male
18 Years+
years
MULTIPLE SITES
Postoperative PainStudy Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy
NCT00468845
  1. Mobile, Alabama
  2. Glendale, Arizona
  3. Phoenix, Arizona
  4. Phoenix, Arizona
  5. Phoenix, Arizona
  6. Glendale, California
  7. Pasadena, California
  8. Miami, Florida
  9. Miami, Florida
  10. Philadelphia, Pennsylvania
  11. Pittsburgh, Pennsylvania
  12. Pittsburgh, Pennsylvania
  13. Houston, Texas
  14. Houston, Texas
  15. Calgary, Alberta
  16. Montreal, Quebec
  17. Sherbrooke, Quebec
  18. Praha 5,
  19. Kowloon,
  20. Shatin,
  21. Johannesburg, Gauteng
  22. Krugersdorp, Gauteng
  23. Pretoria, Gauteng
  24. Newcastle, KwaZulu Natal
  25. Ladysmith, KZN
  26. Cape Town, Western Cape
  27. Parktown,
  28. Cadiz,
  29. Madrid,
  30. Madrid,
  31. Valencia,
  32. Lund,
  33. Orebro,
  34. Stockholm,
  35. Bangkoknoi, Bangkok
  36. Muang, Chiang Mai
  37. Muang, Khon Kaen
  38. Leicester, Leicestershire
  39. Edinburgh, Scotland
  40. Birmingham,
  41. Liverpool,
  42. Livingstone,
Female
25 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery
Official Title  ICMJE A Prospective, Randomized, Double-Blind, Double-Dummy, Multi-Center Study Comparing Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery
Brief Summary To validate the analgesic efficacy and safety of celecoxib compared with ibuprofen SR in the management of acute pain post orthopedic or gynecological surgery
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Pain, Postoperative
Intervention  ICMJE Drug: celecoxib and ibuprofen SR
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 6, 2005)		132
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE July 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Undergone uncomplicated orthopedic surgery or abdominal gynecological surgery under epidural anesthesia
  • Baseline pain intensity of more than 45 mm as measured by VAS and a severity of pain graded as moderate or severe on the categorical pain intensity scale

Exclusion Criteria:

  • A previous history of intolerance or hypersensitivity to any NSAIDs, cyclooxygenase inhibitor, sulfonamides, or any analgesic, or to drugs with similar chemical structures
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00150280
Other Study ID Numbers  ICMJE A3191086
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP